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Treatment of MCF-7 cefls with 1.0 /tM 3-methykholanthrene
(MC) caused a decrease in cell proliferation and
[3H]thymidine uptake whereas no effects were observed at
a lower (0.1 /iM) concentration. Co-treatment of the ceDs with
1 nM 17/3-estradiol plus 0.1 or 1.0 ^ MC resulted in a
significant inhibition of 17/3-estradiol-induced growth and
[3H]thymidine uptake. MC also inhibited the 17/3-estradiol-
induced secretion of the 52 kDa protein (procathepsin D) in
MCF-7 cells and caused a concentration-dependent decrease
in the nuclear estrogen receptor (ER) as determined by either
velocity sedimentation analysis or immunoquantitation with
human ER antibodies. The effects of several different
polynuclear aromatic hydrocarbon (PAH) congeners on the
nuclear ER in MCF-7 cells were also determined. Only those
congeners which bound to the aryl hydrocarbon (Ah)
receptor, namely benzo[a]pyrene, benz[a]anthracene,
7,12-dimethylbenz[a]anthracene and MC, caused a decrease
in nuclear ER levels. In contrast, benzoLg/u'Jperylene, a
congener which did not bind to the Ah receptor did not affect
nuclear ER levels in MCF-7 cells. Moreover, with some
congeners the decrease in nuclear ER levels could be observed
without any significant induction of ethoxyresorufin O-
deethylase activity, a P4501Al-dependent monooxygenase.
These data suggest that the Ah receptor liganded with MC
and related PAHs induced a broad spectrum of antiestrogenk
responses in MCF-7 cells and complements the results of
previous studies which report the antiestrogenic effects of
2,3,7,8-tetrachlorodibenzo-p-dioxin and other halogenated
aromatics which are also Ah receptor agonists.
Introduction
3-Methylcholanthrene (MC*) is a member of the polynuclear
aromatic hydrocarbon (PAH) family of compounds which exhibit
a broad spectrum of biochemical, toxic and genotoxic responses
in laboratory animals and mammalian cells in culture (1 —5). For
example, MC, benzo[a]pyrene, 7,12-dimethylbenz[a]anthracene
and other PAHs have been characterized as carcinogens in
laboratory animals and may be involved in the etiology of human
cancers associated with exposure to PAH mixtures in coal tar
and smoke (6-8) . The carcinogenic activity of these compounds
is dependent on their metabolic activation to reactive intermediates
which alkylate critical target genomic sites (1 —3,9). In addition,
•Abbreviations: MC, 3-methylcholanthrene; PAH, polynuclear aromatic
hydrocarbon; Ah, aryl hydrocarbon; TCDD, 2,3,7,8-tetradecanoyl-
phorbol-13-acetate; XRE, xenobiotic responsive element; DRE, dioxin responsive
element; BSA, bovine serum albumin; <*NF, or-naphthoflavone; DMSO,
dimethylsulfoxide; EROD, ethoxyresorufin 0-deethylase; ER, estrogen receptor;
DCC, dextran-coated charcoal; TCA, trichloroacctic acid.
many of the carcinogenic PAHs such as MC, benzo[a]pyrene
and 7,12-dimethylbenz[a]anthracene exhibit high binding affinity
for the aryl hydrocarbon (Ah) receptor (10). The Ah receptor
is an intracellular protein which has been widely identified in
mammalian cells and tissues (11). It binds with high affinity not
only to PAHs, but also to other structural classes of aromatic
compounds, including the toxic halogenated aromatic hydro-
carbons, typified by 2,3,7,c^tetrachlorodibenzo:p-dioxin (TCDD)
(12-15). TCDD, MC and related isostereomers induce CYP1A-1
gene expression and the molecular mechanism of this response
has been extensively investigated (16-20). The results of these
studies suggest that TCDD or MC reversibly binds to the Ah
receptor; the liganded Ah receptor complex is transformed to
a heterodimer which undergoes nuclear translocation and interacts
with specific binding genomic sites in the 5'-flanking region of
the CYPIA-1 gene. These sites have been designated as xenobiotic
or dioxin responsive elements and the interaction of the nuclear
Ah receptor complexes with these sites is necessary for induced
gene transcription. The nuclear Ah receptor complex liganded
with TCDD, MC and related compounds acts as a ligand-
responsive transcription factor (21) which is involved in the
induction of Ah-responsive genes.
TCDD elicits a broad spectrum of age, species-, sex- and
organ-/cell-specific responses which are also believed to be
mediated through the Ah receptor (13,15,17). For example
TCDD inhibits several 17/3-estradiol-induced responses in the
female rodent and in human breast cancer cell lines (22,23). The
Ah receptor has been identified in the target issues (e.g. rat uterus)
and cells (24—27) and, based on structure—activity studies with
related congeners, the results support a direct or indirect role
for the Ah receptor in this process. The effects of other Ah
receptor agonists as antiestrogens have not been determined.
Therefore, this study is focused on the activity of MC and related
PAHs on several estrogen-induced responses in MCF-7 human
breast cancer cells.
Materials and methods
Chemicals and biochemicals
MC, l,2-benzfa]anthracene, 7,12-dimethylbenz[a]anthracene, benzo{a]pyrene,
benzolg/Dlperylene, NADP, NADPH, rhodamine B, bovine serum albumin (BSA)
and transferrin were purchased from Sigma Chemical Co. (St. Louis, MO), a-
Naphthoflavone (<*NF) was purchased from the Aldrich Chemical Co. (Milwaukee,
WI). Radiolabeled [3H]170-estradiol (143 Ci/mmol) and [3H]thymidine
(73.5 Ci/mmol) were purchased from New England Nuclear Research Products
(Boston, MA). Hydroxylapatite was purchased from Bio-Rad Laboratories (La
JoIIa, CA) and all other chemicals were of the highest quality available from
commercial sources.
Cell culture growth
MCF-7 human breast cancer cells were grown in DME/F12 media (Gibco,
Gaithersburg, MD) supplemented with 2.2 g/1 tissue grade sodium bicarbonate,
0.2 g/1 bovine serum albumin, 10 mg/1 transferrin, 5% fetal calf serum and a
1% antibiotic—antimycotic solution. Stock cultures were grown in 150 cm2
culture flasks and incubated at 37°C in 95% air and 5% COi. For enzyme
assays, 5 x 106 cells in 5 ml of media were passaged to 25 cm2 culture flasks.
For nuclear experiments, 5 x 107 cells in 50 ml of media were passaged
to 150 cm2 culture flasks. Solutions of the treatment chemicals dissolved in
dimethylsulfoxide (DMSO) were added to the tissue culture flasks so that the
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final concentration of DMSO did not exceed 0.1%. Cultured MCF-7 cells were
harvested and assayed for enzyme induction 24 h after treatment unless other-
wise specified and 12 h after treatment for the nuclear extraction studies.
Induction of ethoxyresorufin O-deethylase (EROD) activity
The cells were harvested and the EROD activity was determined by the method
of Pohl and Fouts as previously described (28). Protein concentrations were
determined by the method of Lowry et al. (29).
Preparation of nuclear extracts
MCF-7 cells were rinsed with 20 ml of phosphate-buffered saline (PBS) to remove
any traces of the chemical treatments and harvested by trypsinization. Six
150 cm2 culture flasks were used per treatment group. Cells from each treatment
group were collected in warm PBS, pooled into 50 ml polypropylene conical
centrifuge tubes and centrifuged at 800 g (2°C) for 10 min. The resulting pellet
was resuspended in 20 ml of DME/F12 media, syringed five times to ensure
a single-cell suspension and aUquoted equally into two 25 cm2 culture flasks. The
cellular suspension was treated with either 1 nM [3H]170-estradiol or 1 nM
[3H] 17|3-estradiol plus a 200-fold excess of diethylstilbesterol (for determination
of nonspecific binding) for 60 min at 37°C in a shaking water bath. Following
the 60 min radioligand treatment, the cell suspension was transferred to 50 ml
polypropylene conical centrifuge tubes and centrifuged at 800 g (62°Q for 10 min.
The resulting pellet was then rinsed twice in TEGD buffer (10 mM Tris-HCl,
1.5 mMEDTA, 10% glycerol, 1 mM dithiothreitol pH 7.6) and pelleted by centri-
fugation at 800 g (2°Q for 10 min. The washed cell pellet was resuspended in
TED buffer (10 mM Tris-HCl, 1.5 mM EDTA, 1 mM dithiothreitol pH 7.6)
and transferred to a 2 ml Wheaton homogenizing tube. The samples were
homogenized with 15 passes of a Teflon pestle/drill apparatus. The homogenate
was transferred to a 15 ml polypropylene conical centrifuge tube to which 2 ml
of TEGDM buffer (10 mM Tris-HCl, 1.5 mM EDTA, 10% glycerol, 1 mM
dithiothreitol, 20 mM sodium molybdate pH 7.6) was added. The sample was
centrifuged at 100 g (2°Q for 10 min and the resulting pellet rinsed twice with
5 ml of TEGDM. After the final wash, the pellet was resuspended in 2 ml of
TEGDM containing 0.4 M KC1, to extract the receptor—ligand complex, in a
5 ml polycarbonate Beckman centrifuge tube. The suspension was incubated at
2°C for 1 h before centrifugation at 105 000 g (2°C) for 1 h. The resulting super-
natant was used for sucrose density gradient analysis or direct liquid scintillation
counting.
Sucrose density gradient analysis
Aliquots (1 ml) of the supernatant were briefly treated with dextran/charcoal
solution (0.2 mg charcoal and 0.02 mg dextran) in order to remove any unbound
or loosely bound [3H]17/3-estradk>l. The dextran/charcoal was removed after a
15 min incubation by centrifugation at 1000 g (2°Q for 10 min. Aliquots (300 jd)
of the supernatant were layered onto a linear 5-25% sucrose density gradient
prepared in TEGDM buffer containing 0.4 M KC1. Gradients were then sealed
and centrifuged at 404 000 # (2"Q for 2.5 h in a Beckman VTi-65 vertical rotor.
The gradient was fractionated into 30 fractions with 4 drops/fraction. Radioactivity
of each fraction was determined by liquid scintillation counting.
Measurement of nuclear estrogen receptor (ER) by monoclonal antibody kit from
Abbott Laboratories (83-5167/R5)
Nuclear extracts were prepared as described above. Lyophilized standards were
prepared as described in the instructions enclosed in the kit. Each sample was
assayed in triplicate, and 100 ul of nuclear extract were used per well. Each sample
was diluted with the specimen diluent provided in the kit. One estrogen receptor
bead was placed into each well containing either the sample extract, the standard
or the control. The trays were then incubated for 16 ± 1 h at 2°C. Following
the incubation period, each bead was washed twice with 6 - 8 ml of deiorrized
water. ER conjugate was put into each well and incubated in water bath at 37 °C
for 1 h. After the incubation with the ER conjugate, the beads were again rinsed
twice with 6—8 ml of deionized water. The beads were transferred to test tubes,
and 300 /d of O-phenylenediamine-2 HC1 substrate solution was added. The
absorbance was read at 492 nm using a Beckman DU-70 spectrophotometer with
deionized water as a blank. Concentrations of the nuclear estrogen receptor were
calculated from a standard curve, with the results being reported as fmol of nuclear
estrogen receptor/mg nuclear protein.
Cell proliferation assays
A cellular suspension containing 25 000 cells/ml was made with DME/F12
supplemented with 3% 2 x dextran-coated charcoal (DCQ CPSR-2 and 5%
2 x DCC FCS (both sera had previously been stripped twice with an 0.05%
dextran, 0.5% charcoal solution for 30 min at 56°C); 50 000 cells (2 ml of the
suspension) were then seeded into a six-well tissue culture plate and incubated
at 37°C with a 5% COj and 95% air atmosphere. After 24 h, the medium was
replaced with DME/F12 plus 3% 2 x DCC CPSR-2 and 1% 2 x DCC FCS
medium containing the appropriate treatment chemicals. The media and chemicals
were changed every second day. At the end of seven days, the cells were harvested
and counted using a hemocytometer.
[3H]Thymidine incorporation assay
The cells for the [3H]thymidine incorporation assay were grown and treated in
the same conditions as outlined in the cell proliferation assay section with the
following exceptions: (1) 100 000 cells were seeded per well, and (2) the dosing
period consisted of only 4 days. After dosing for 4 days, the cells were pulsed
for 1 h with 1 pCi [3H]thymidine per well at 37°C prior to harvesting. The
medium was subsequently removed and the wells were rinsed twice with cold
PBS. Two milliliters of cold 10% trichloroacetic acid (TCA) was added to each
well, and the plates were placed on ice for 4 h to precipitate the protein. The
cells were then scraped from the wells, rinsed twice with 2 ml of 10% TCA
and transferred to 15 ml polypropylene conical centrifuge tubes. The 15 ml tubes
were centrifuged at 2500 g (2°C) for 10 min. The supernatant was decanted and
the pellets rinsed twice with 10% TCA, followed by a final rinse with 1 ml of
cold absolute ethanol (2500 g at 2°C for 10 min). After the final rinse, the pellets
were resuspended in 0.3 M sodium hydroxide solution to solubilize the protein.
The protein was allowed to solubilize for 18 h at 20°C. The samples were vortexed
and three 50 /J aliquots transferred to scintillation vials; 2.5 /il of 2 N hydrochloric
acid was added to neutralize die base; 5 ml of Ecoscint A scintillation cocktail
was also added to the scintillation vial. Radioactivity was determined by liquid
scintillation counting.
Detection of the 52 kDa protein (cathepsin D)
MCF-7 cells were grown and maintained in RPMI 1640 medium supplemented
with 2 x DCC-FCS. On day 1 cells were passaged into 150 cm2 culture flasks
containing DME/F12 medium supplemented with 5% 2 x DCC-FCS and 3%
2 x DCC CPSR-2. On day 3 cells were seeded into six-well tissue culture plates
at a density of 50 000 cells/ml of the DME/F12 medium. On day 4 the medium
was changed to the above medium containing 1 % 2 x DCC-FCS. On day 5 cells
were washed with PBS and treated with fresh medium which contained the
appropriate chemicals. After 42 h the cells were washed with PBS and 750 /tl
of serum-free DME/F12 medium phis the appropriate chemicals was added. After
6 h the medium was removed for further analysis. The treatment chemicals were
dissolved in absolute ethanol (1 % v/v). The protein concentration in each sample
was determined by using the method employed by Lowry et al. (29).
Double staining procedure
The secreted proteins were analyzed by SDS-PAGE. Five micrograms of each
sample were loaded onto a 12% acrylamide gel slab with a 3% stacking gel.
Gels were washed in 12% TCA overnight and incubated in the pretreatment
solution for 60 min followed by 30-60 min of staining in the ISS ProBlue™
staining solution (30). The time for staining varied with the amount of protein
on the gel. The gels were then washed five times for 2 min with deionized water
followed by fixing the gels in a 50% methanol, 10% acetic acid aqueous solution
for 30 min. The fixation was further continued overnight in a 5% methanol, 7%
acetic acid aqueous solution. The gel was treated with 10% ghttaraldehyde solution
for 30 min followed by four 30 min washes with deionized water. The gels were
then stained with ammoniacal silver stain solution for 15 min with vigorous
shaking. The excess solution was washed off die gel using five 1 min washes
with an excess of deionized water. The bands were developed using the developing
solution (0.5 g sodium citrate, 0.5 ml of 37% formaldehyde solution) until the
desired intensity was reached. The stain was fixed onto the gel using the Kodak
Rapid Fix™ solution with mild agitation for 5 min. The excess rapid fix was
washed off using deionized water. The gel was then dried and subjected to further
analysis using a scanning laser denshometer.
Statistics
All die treatment groups were performed in triplicate and the results are presented
as means ± SD. The significant differences between different treatment groups
were determined by ANOVA or Student's »-test.
Results
The results in Table I summarize the effects of 1 nM 17/3-
estradiol, 0.1 and 1 /xM MC and their combinations on the
proliferation and [3H]thymidine uptake in MCF-7 human breast
cancer cells. 17/3-Estradiol significantly increased cell
proliferation and [3H]thymidine uptake; 0.1 uM MC alone did
not increase cell growth of [3H]thymidine uptake whereas
1.0 /xM MC inhibited both growth and incorporation of
[3H]thymidine into cellular DNA. In the co-treatment studies,
MC (0.1 and i.O /tM) caused a concentration-dependent decrease
in 17/3-estradiol-induced cell proliferation and [^HJthymidine up-
take in MCF-7 cells.
The effects of MC on the 17/3-estradiol-induced secretion of
the 52 kDa protein (procathepsin) in MCF-7 cells was also
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Table I. Effects of MC on the 17/S-estradic4-stimulated cell proliferation and
[3H]thymidine uptake in MCF-7 cells*
Treatment Concentration [3H]Thymidine Cell no
(d.p.m./^g protein) (x 10~4)
Control (DMSO)
17/3-estradiol
MC
MC
17/3-estradiol + MC
17/3-estradiol + MC
0
0.001
0.1
1.0
0.001 + 0 . 1
0.001 + 1.0
2260 ± 586
4000 ± 416*
1730 ± 351
1060 ± 88.0=
2324 ± 6471
917 ± 340d
22
55
29
13
34
11
± 4.0
± 3.0"
± 4.0
± 0.3c
± 6.0"1
± l.ff1
•The MCF-7 cells (50 000) were treated with the solvent (DMSO) vehicle
control, 17/S-estradiol, MC and MC plus 17/3-estradiol and the media and
treatments were changed very 48 h. The cells were counted after 7 days
using a hemocytometer. The [3H]thymidine assays were determined after
growth of MCF-7 cells (100 000 seeded) for 4 days using a 1 h pulse of
[3H]thymidine; the DNA was isolated from the cells as described in the
Materials and methods and quanlitated by liquid scintillation counting.
""Significantly higher (P < 0.01) than values for control cells.
cSignificantly lower (P < 0.01) than values for control cells.
dSignificantly lower (/> < 0.01) than values for cells treated with 17/3-
estradiol alone.
TaWe II. Effects of MC, 17/3-estradiol and MC plus 17/3-estradiol on the
secretion of the 52 kDa protein in MCF-7 cells'
Treatment (concentration, Relative levels of secreted
52 kDa protein (% of control)
Control (DMSO)
17j3-estradiol (0.001)
MC (0.1)
MC (1.0)
17/3-estradiol (0.001)
17/3-estradiol (0.001)
+ MC
+ MC
(0.1)
(1.0)
100
278
97
88
165
105
±
±
±
±
±
±
11
24"
8
7
Y
"The MCF-7 cells (50 000) were seeded in multiwell culture plates and after
attachment were treated with the solvent (DMSO) vehicle control and the
various chemicals for 42 h; the cells were then washed and treated with the
same chemical in serum-free media for 6 h. The secreted proteins were
separated by SDS-PAGE, double-stained with ISS ProBhie™ and a silver
stain and finally quantitated by densitometric analysis as described in the
Materials and methods section.
bSignificantly higher (P < 0.01) than values for control cells.
'Significantly lower (P < 0.01) than values for cells treated with 17/3-
estradiol alone.
determined (Table II) by densitometric analysis of the double-
stained gel used to separate the proteins secreted into the media
from the cells treated with different chemicals (Figure 1). The
levels of the secreted 52 kDa protein in the cells treated with
1 nM 17/3-estradiol were 278% of the control cell values wheres
in cells treated with 0.1 or 1.0 /M 3-MC there were no significant
changes in the 52 kDa protein levels compared with the solvent-
treated control cells. In contrast, in the cells co-treated with MC
plus 17/3-estradiol, MC caused a significant concentration-
dependent decrease in the levels of the 17/3-estradiol-induced
protein.
The concentration-dependent effects of MC on nuclear ER
levels were determined using both radioligand binding assays
(velocity sedimentation analysis) (Figure 2) and immuno-
quantitation with a commercially available monoclonal antibody
kit. The absolute values for the nuclear ER for the control cells
differed according to the method of analysis and some of these
differences may be due in part to the cell passage number since
nuclear ER levels tend to decrease with increasing passage
number. The results in Table in show that the percentage
PAH carcinogens as anttestrogens
• yy>w
52.0-
-97.4
•66.2
-45.0
-31.0
Fig. 1. Double staining of the SDS—PAGE separation of media proteins
from MCF-7 cells treated with 17/3-estradiol, MC and their combinations.
The separation and staining procedures are given in the Materials and
methods section. In this chromatogram, aliquots of the media from cells
treated with (left to right) solvent (DMSO), 1 nM 17/3-estradiol (E2), 1 nM
170-estradiol plus 1 ptm MC, 1 nM 17/3-estradiol plus 0.1 /M MC, 1.0 /iM
MC and 0.1 fiM MC were applied to the gel and separated by
SDS-PAGE. The position of the molecular weight markers are also noted.
2000
1000-
10 2 0
Fraction No.
Fig. 2. Velocity sedimentation analysis of nuclear extract from MCF-7 cells
treated with 1 nM [3H] 17/3-estradiol (D), 1 nM [3H] 17/3-estradiol plus
0.1 /iM MC ( • ) , and 1 nM [3H] 17/3-estradiol plus a 200-fold molar excess
of unlabeled diethylstilbestrol ( • ). The sucrose-density gradient
centrifugation procedure is noted in the Materials and methods section;
[14C]catalase and bovine serum albumin were used as molecular weight
markers as described (34).
decreases in nuclear ER levels in MCF-7 cells treated with
different concentrations of MC were similar using both assay
systems. The results in Table IV summarize the effects of aNF
and several different PAH congeners on nuclear ER levels
in MCF-7 cells. Benzo[a]pyrene, benz[a]anthracene and
7,12-dimethylbenz[a]anthracene cause a concentration-dependent
decrease in nuclear ER levels whereas benzo[g/u]perylene was
inactive at the same concentrations (0.1 and 1.0 /iM). The results
also showed that 1 fiM aNF, an Ah receptor antagonist, did not
decrease nuclear ER levels but significantly protected against the
MC-induced decrease of the nuclear ER.
The recovery of nuclear ER levels after treatment with MC
was also determined in MCF-7 cells. The cells were initially
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Table HI. Concentration-dependent decrease of the nuclear ER in MCF-7
cells treated with M C
Table V. Time-Dependent effects of 0.1 /iM MC on nuclear ER levels in
MCF-7 human breast cancer cells*
Treatment
(dose, pM)
Nuclear ER levels
(fmol/mg protein)
(% control)
Immunoreactive nuclear
ER levels
(fmol/mg protein)
(% control)
Treatment Pretreatment time Nuclear ER levels
DMSO (control)
MC (0.001)
MC (0.01)
MC (0.1)
MC (1.0)
MC (10.0)
160
167
146
99
51
48
±
±
±
±
±
±
9.0
8.0
5.0
4.0
1.0
1.0
(100)
(104)
(91)
(62)"
(32)"
(30)"
312
316
317
221
189
94
±
±
±
±
±
±
12 (100)
12 (101)
3.7 (102)
28 (71)"
16 (61)"
5.0 (30)"
The MCF-7 cells were grown in 150 cm2 flasks (6 per treatment group)
and treated with the various chemicals. After isolation of the cells, they
were suspended in growth media for 2 h at 37°C in the presence of 1 nM
[3H]17/3-estradiol in the absence or presence of 200 nM diethylstilbesterol.
Nuclear extracts were obtained from the suspended cells and the
specifically-bound nuclear ER levels were determined by velocity
sedimentation analysis or by immunoassay procedures as described in the
Materials and methods section.
"Significantly lower (P < 0.01) than values for control cells.
Tabte IV. Effects of MC, aNF, MC plus aNF, Benz(a]anthracene
Benzo[a]pyrene, 7,12-Dirnethylbcnz[a]anthracene and Benzo[^/u]perylene on
nuclear ER levels in MCF-7 cells"
Treatments (concentration, Nuclear ER levels (% control)
DMSO
Benzo{a]pyrene (0.1)
Benzo{a]pyrene (1.0)
Benz[a]anthracene (0.1)
Benz(a]anthracene (1.0)
7,12-Dimethylbenz[a]anthracenc (0.1)
7,12-Dimethylbenz|>]anthracene (1.0)
Benzo{g/u]perylene (0.1)
Benzo{sM]perylene (1.0)
DMSO
aNF (1)
MC (0.1)
aNF (1) + MC (0.1)
100 ± 12
75 ± 10"
30 ± 9"
51 ± 8"
24 ± 6"
44 ± 9"
30 ± 2"
113 ± 3
99 ± 3
100 ± 8
100 ± 3
38 ± 2"
70 ± 6C
"The cell growth, treatment protocols and nuclear ER levels (velocity
sedimentation analysis) were determined as described in Table HI and the
Materials and methods section.
"Significantly lower (P < 0.01) than values for control cells.
'Significantly higher (P < 0.01) than values for cells treated with 0.1 fM
MC alone.
treated with 0.1 /tM MC 12 h before the addition of 1 nM
[3H]17/3-estradiol and nuclear ER levels were determined 1 h
after addition of the radiolabeled hormone. The recovery
experiment were determined by increasing the MC pretreatment
times from 12 to 18, 24, 30, 36 and 48 h. The results show that
there was a time-dependent recovery of the cells from MC and,
after 36 or 48 h exposure to MC, no significant decreases in ER
levels were observed (Table V).
The effects of several PAH congeners on the induction of
EROD activity in MCF-7 cells was also determined (Table VI).
These data show that after treatment of the cells for 12 h, < 10%
maximal induction was observed for 0.1 and 1.0 /tM MC and
1.0 nM TCDD whereas higher levels of induced EROD activity
were observed for 1 /tM benz[a]anthracene and 1 nM TCDD
12 and 24 h after treatment of the cells.
Control (DMSO)
MC
MC
MC
MC
MC
MC
(h)
_
12
18
24
30
36
48
fmol/mg protein
221 ±
134 ±
136 ±
174 ±
206 ±
223 ±
216 ±
3.1
4.0"
17"
5.8"
4.4"
12
4.5
% control
100 ±
61 ±
61 ±
79 ±
93 ±
101 ±
98 ±
1.4
2.3"
13"
3.3"
2.1"
5.4
2.1
"The cell growth, treatment protocols and nuclear ER levels (velocity
sedimentation analysis) were determined as described in Table HI and the
Materials and methods section. The standard pretreatment time for MC was
12 h; however, in this experiment cells were also pretreated for 18, 24, 30,
36 or 48 h with MC prior to addition of the radiolabeled hormone.
"Significantly lower (P < 0.01) than values for control cells.
Table VI. Effects of selected PAHs and
EROD activity in MCF-7 human breast
Treatment
(concentration, /M)
MC(0.1)
MC (1.0)
Benz(a]anthracene (0.1)
Benz[a]anthracene (1.0)
Benzo{a]pyrene (0.1)
Benzo[a]pyrene (1.0)
7,12-Dimethylbenz(a]anthracene (0.1)
7,12-Dimcthylbenz[a]anthracene (1.0)
Benzo(gW]perylene (0.1)
Benzotj/u]perylene (1.0)
2,3,7,8-TCDD (0.001)
2,3,7,8-TCDD (0.001)
DMSO (control)
2,3,7,8-TCDD on
cancer cells*
Duration
(h)
12
12
12
12
12
12
12
12
12
12
12
24
the induction of
EROD activity
(pmol/min/mg)
5 ± 1"
4 ± l"
ND
36 ± 2"
ND
ND
ND
ND
ND
ND
8 ± 0.1
85 ± 18
ND
"The MCF-7 cells were treated with different concentrations of the
individual PAH or 2,3,7,8-TCDD for 12 h or with 2,3,7,8-TCDD for 24 h
and the EROD activity was determined as described (28). ND, not
detectable.
"Significantly higher (P < 0.01) than values for control cells.
Discussion
Human breast cancer cell lines have been widely used as models
for investigating the effects of various mitogenic and
antimitogenic agents on cell proliferation and gene transcription
(31-33). MCF-7 cells were selected for this study since these
cells express both the estrogen and the Ah receptor and are
responsive to agonists which bind to these receptor proteins (27).
Like TCDD and several structurally related halogenated aryl
hydrocarbons (34—36), MC elicits a similar spectrum of
antiestrogenic responses. For example, 0.1 /tM MC inhibited
17/3-estradiol-induced cell proliferation and [3H]thymidine
uptake and the secretion of the 52 kDa protein (Tables I and IT).
In addition, 1.0 /tM MC also inhibited constitutive MCF-7 cell
growth and [3H]thymidine uptake. The results in Table III also
demonstrate that MC decreased nuclear ER levels as determined
by velocity sedimentation analysis and immunoreactive protein
which was measured using a human ER antibody kit.
The antiproliferative effects caused by MC are not unique since
many different structural classes of compounds elicit some of
the same responses. For example, recent studies have reported
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that 12-0-tetradecanoylphorbol-13-acetate (TPA), protein kinase
C activators and several other differentiation-inducing agents
including retinoic acid, sodium butyrate, dimethylformamide,
hexamethylene bisacetamide, forskolin, the calcium ionophore
A23187, TCDD and related isostereomers inhibit MCF-7 cell
growth and decrease nuclear ER levels in MCF-7 cells (35 -42).
TPA also inhibited 17/3-estradiol-induced growth and decreased
17/3-estradiol-induced immunoreactive progesterone receptor
levels (39—42), and similar results have been observed for both
TCDD and MC (33,43). In contrast, TPA did not inhibit
estrogen-induced pS2 or procathepsin D gene expressions (39),
and it was concluded that the growth inhibitory properties of TPA
were not due to inhibition of estrogen-induced gene transcription.
In contrast, the results shown in Table II indicate that MC, like
TCDD, inhibited the estrogen-induced secretion of procathepsin
D in MCF-7 cells. Moreover, in vivo studies in this laboratory
(R.Dickerson, unpublished results) have shown that MC, like
TCDD, inhibited the 17/3-estradiol-induced uterine wet weight
increase and uterine progesterone receptor levels in female
Sprague-Dawley rats. Thus, both MC and TCDD exhibited a
broad spectrum of antiestrogenic activities which more closely
resembled the ER antagonists ICI 164,384 (44,45) than TPA and
the differentiation-inducing agents.
MC and TCDD have been extensively used as prototypes for
investigating the molecular biology of CYP1A1 gene expression
(16—20). Structure—activity relationships among the polynuclear
and halogenated aromatic hydrocarbons have shown a correlation
between the structure Ah receptor binding versus structure-
induction (P4501A1) activities for both sets of compounds
(10,15). MC, benzo[a]pyrene, benz[a]anthracene and
7,12-dimethylbenz[a]anthracene all bind to the Ah receptor and
induce aryl hydrocarbon hydroxylase and EROD activity (10).
The results summarized in Table IV also show that these Ah
receptor agonists cause a decrease in nuclear ER levels. In
contrast, benzo[g/u]perylene, a ligand which does not exhibit
significant binding to the Ah receptor (10), does not cause a
decrease in nuclear ER levels in MCF-7 cells. The effects of aNF
on the antiestrogenic activity of MC also supports the role of
the Ah receptor in the cross-talk between the two endocrine
systems. aNF, an Ah receptor antagonist (46,47), significantly
inhibited the MC-induced decrease in nuclear ER levels (Table
TV) and these data coupled with similar correlations between the
structure—binding and structure—antiestrogenicity relationships
for TCDD and related halogenated aryl hydrocarbons support
a role for the Ah receptor in this process.
The recovery of nuclear ER levels in MCF-7 cells treated with
MC was also investigated. Twelve hours after treatment with
0.1 /xM MC, a 39% decrease in nuclear ER levels was observed
(Table V) and significant reduction of the nuclear ER was
maintained in cells treated with MC for up to 24 h. However,
in cells exposed to MC for 30 h, the nuclear ER levels were
decreased by < 10% and returned to control levels 36 h after
initial exposure to MC. These results suggest that the effects of
MC on nuclear ER levels are reversible and this may be due to
the metabolism of MC in MCF-7 cells.
At least two different mechanisms have been proposed for the
Ah receptor-mediated antiestrogenic responses in human breast
cancer cell lines. Safe et at. have proposed that the antiestrogenic
responses require the induction of unknown genes whose products
inhibit estrogen-induced gene transcription (22,23). In contrast,
Gierthy et at. have demonstrated that TCDD-induced CYP1A1
gene expression results in increased 17j3-estradiol metabolism
and they propose that the induced metabolism of the hormone
is responsible for decreased hormone responsiveness (48,49). The
results in Table VI summarize the induction of EROD activity
by MC, benz[a]anthracene, 7,12-dimethylbenz[a]anthracene,
benzo[a]pyrene, benzo[^/u]perylene and TCDD 12 h after
addition of the inducer and also 24 h after the addition of
TCDD. At this time point, benzo[a]pyrene and 7,12-
dimethylbenz[a]anthracene did not induce EROD activity
and < 10% of the maximum induced activity was observed for
MC. These data are consistent with the hypothesis that induced
CYP1A1 gene expression is not required for the Ah receptor-
mediated antiestrogenic responses. It should be noted that 1 /tM
benz[a]anthracene induced exceptionally high levels of EROD
activity within 12 h (Table VI) and this was accompanied by the
largest decrease (76%) in nuclear ER levels (Table TV). These
data confirm that, at least for the higher concentration of
benz[a]anthracene, the induction of P4501A1 and the subsequent
increased metabolism of 17/3-estradiol may also significantly
contribute to the observed antiestrogenic responses.
Epidemiological studies have reported that cigarette smoking
is associated with diverse antiestrogenic responses in women and
these include a reduction in the risk from endometrial cancer,
earlier onset of menopause and increased osteoporosis (50—55).
The effects of cigarette smoking on breast cancer in women is
unclear; however, the results suggest that any protective effects
are minimal (56—58). Michnovicz et at. (59) have suggested that
increased estradiol-2-hydroxylase activity in women who smoke
may be responsible for the antiestrogen activity of cigarette
smoking; this result is consistent with the induction of both
CYP1A1 and CYP1A2 gene expression by PAHs in cigarette
smoke since P4501A1 and P4501A2 enhance 17/3-estradiol
metabolism (48,49,60). However, based on the results of the
present study, antiestrogenic activity of the PAHs may also be
due to Ah receptor-mediated responses which are independent
of induced CYP1A1 and CYP1A2 gene expression.
Current studies in this laboratory are focused on delineating
the mechanism of Ah receptor-mediated antiestrogenicity and
identifying the induced gene products associated with this
response.
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